Advertisement

Management of Autoimmune and Inflammatory Disorders in the Setting of Infection or Immunodeficiency

  • W. Winn ChathamEmail author
Chapter

Abstract

Host-microbiome symbiosis is contingent upon intact immune surveillance and competence. Compromised immunity with development of clinical infection may occur as a consequence of immunosuppressive therapy prescribed for treatment of inflammatory or autoimmune disease. Alternatively, autoimmune disorders not uncommonly develop in the context of underlying immune deficiency. In either setting, clinicians may need to develop strategies to suppress autoimmune-mediated inflammation in the setting of intercurrent infection. The optimal strategy is best informed by what host defenses are required to effect resolution of the infection, the current status of these defenses in a given patient, and recognition of how chosen therapies for managing autoimmunity and associated inflammation may (or may not) impact the ability of the needed defenses to eradicate specific pathogens.

Keywords

Autoimmune diseases Immunosuppressive therapy Infection Immunodeficiency 

Abbreviations

ADA

Adenosine deaminase deficiency

AICDA

Activation-induced cytidine deaminase

CVID

Common variable immunodeficiency

DMARD

Disease-modifying antirheumatic drug

GCA

Giant cell arteritis

GPA

Granulomatosis with polyangiitis

IL

Interleukin

IL-6R,IL-17R

Interleukin 6 (17) receptor

IVIG

Intravenous immunoglobulin

MBL

Mannose-binding lectin

MMP

Matrix metalloproteinase

MPA

Microscopic polyangiitis

MTX

Methotrexate

NSAID

Nonsteroidal anti-inflammatory drug

PAN

Polyarteritis nodosa

PID

Primary immunodeficiency

RA

Rheumatoid arthritis

sIgA

Selective IgA deficiency

SLE

Systemic lupus erythematosus

SNSA

Seronegative spondyloarthritis

TACI

Transmembrane activator, calcium-modulator, and cyclophilin ligand interactor

TLR

Toll-like receptor

UNG

Uracil nucleoside glycosylase

WAS

Wiskott-Aldrich syndrome

XLA

X-linked agammaglobulinemia

Managing Autoimmune Disorders in the Setting of Acquired Infection

Rheumatoid Arthritis

Infection risk is increased in rheumatoid arthritis (RA) , primarily in the context of high disease activity and intercurrent use of corticosteroids [1, 2]. Risk of joint sepsis is increased due to hypervascular, proliferative synovium permitting easy access of circulating microbial pathogens into affected joints. RA patients with Felty’s syndrome may be at even greater risk due to the leucopenia and hypersplenism associated with this RA complication. Traditional disease-modifying antirheumatic drugs (DMARDs) as well as biologic DMARDs targeting inflammatory mediators in RA are highly effective in suppressing synovial inflammation and attendant structural damage due to RA. With the possible exception of anti-TNF antibodies, DMARDs have not been shown to significantly increase overall incident infection risk in RA [3, 4, 5]. However, traditional DMARDs such as methotrexate and biologic DMARDs may nonetheless impact host responses to acquired infection.

As a general rule, management of RA in the setting of suspected intercurrent infection entails withholding dosing of therapies known to impact phagocytic cell functions, minimizing corticosteroid dosing to the levels required for avoidance of adrenal crisis, assiduous attention to the possibility of joint seeding by bacteria, and prompt institution of antimicrobial therapy with joint drainage as needed. Nonsteroidal anti-inflammatory drugs (NSAIDs) or intra-articular corticosteroids can be used as needed to manage synovitis flares until infection has resolved. If NSAIDs are contraindicated, low-dose prednisone (5–10 mg/day) and/or non-acetylated aspirin (salsalate) which does not inhibit cyclooxygenase activity can be used for managing generalized joint flares. Considerations in this setting with respect to commonly used RA DMARDs and biologics are summarized below (see Chap. 34 for individual drugs and risk of infection).

Methotrexate

The clinical efficacy of methotrexate (MTX) , one of the most commonly employed DMARDs in the management of RA, is attributed primarily to the inhibitory effects of intracellular MTX polyglutamates on AICAR transformylase, resulting in increased levels of adenosine which is inhibitory for trafficking of phagocytic cells into joints [6]. As such, it is prudent to hold treatment with methotrexate until intercurrent bacterial infections affecting the lungs, skin, joints, or other tissues have clinically resolved. The presumed effect of MTX on immune cell trafficking has traditionally proscribed MTX use perioperatively with conflicting expert opinion on whether MTX should be held in the context of joint replacement procedures. However, recent studies have shifted expert opinion toward not withholding MTX around the time of elective joint replacement surgery, citing the increased morbidity associated with disease flare in this setting [5].

TNF Inhibitors

TNF promotes a variety of phagocytic cell activation responses including expression of adhesion molecules and activation of the respiratory burst in neutrophils. Although in vitro studies with etanercept showed no direct effect on neutrophil phagocytic cell or microbicidal activity [7], inhibition of TNF locally by etanercept or anti-TNF monoclonal constructs may nonetheless impair phagocytic cell-mediated host defenses to microbial pathogens. Indeed, treatment with TNF inhibitors has been shown to confer increased infection risk in multiple cohorts of patients with disorders in which treatment with these agents is included among the employed therapeutic options [4]. TNF also appears to be an important cytokine in maintaining the integrity of granulomas, and the association of anti-TNF therapies with reactivation of tuberculosis and disseminated fungal infections is also well recognized [8, 9]. Thus, prescribing guidelines include testing for latent tuberculosis in all patients newly started on TNF inhibitors. The risk for non-viral opportunistic infection, including tuberculosis, appears to be higher in patients treated with anti-TNF monoclonal reagents such as infliximab relative to that noted in patients treated with sTNFR:Fc /etanercept [10].

Given the increased risk and morbidity of infection complications observed in patients on TNF inhibitor therapy, it is therefore appropriate to withhold and not initiate anti-TNF therapy in the setting of any active infection. Moreover, patients with RA who have comorbidities such as diabetes have a demonstrated increased risk for bacterial infections as well as increased infection-related morbidity during treatment with TNF inhibitors [11]. An alternative to anti-TNF therapy with less direct impact on phagocytic cell responses might therefore best be considered for managing RA in patients with pre-existing comorbidities associated with increased infection risk.

IL-6 Inhibitors

Due to signaling that can occur through the interleukin (IL)-6 receptor (IL-6R) and trans-signaling through gp130 receptors that recognize IL-6:sIL-6R heterodimer, inhibitors of IL-6 such as tocilizumab have pleomorphic effects on immune as well as nonimmune cells. IL-6 mediates activation of macrophages, terminal proliferation and differentiation of B-cells, differentiation of Th17 cells, and also homeostatic processes including granulopoiesis, induction of some anti-inflammatory cytokines, and mucosal integrity [12, 13]. Given these considerations, it is generally prudent to withhold treatment with IL-6 inhibitors such as tocilizumab (anti-IL6R) or sirukumab (anti-IL6) in the setting of intercurrent infection. Since IL-6 signaling appears to govern homeostasis of the enteric mucosal epithelium, and anti-IL-6 therapy has been associated with increased risk of intestinal perforations [14], treatment with IL-6 inhibitors is not recommended in the setting of inflammatory bowel disease, diverticular disease, or recent colitis in which the integrity of the enteric mucosa may become compromised.

Janus Kinase Inhibitors

Janus kinase inhibitors such as tofacitinib block signal transduction mediating the effects of inflammatory cytokines such as TNF and IL-6, with potent inhibitory effects on the functions of phagocytic cells. Reported rates of infection in patients on treatment with tofacitinib are comparable to those reported in patients on anti-TNF or anti-IL6 therapies [15]. The considerations alluded to above for these respective biologics are therefore equally applicable to tofacitinib, and it is advisable to withhold its use in the setting of intercurrent infection, resuming treatment once the infection is deemed resolved. The experience with other Janus kinase inhibitors is limited, but in the absence of data indicating otherwise, treatment with the newer agents is also advisably withheld in the setting of intercurrent bacterial infection.

Abatacept

Effective in blocking T cell co-stimulation and associated acquired responses to neo-antigens, abatacept does not have direct impacts on phagocytic cell responses. Serious bacterial infection occurs less commonly during treatment of RA with abatacept than with TNF inhibitors [16, 17], and risk of reactivation or acquired infection with tuberculosis is lower among RA patents treated with abatacept relative to those treated with TNF inhibitors [18]. Whether it is necessary to withhold treatment with abatacept in the setting of acute bacterial infection has not been established. Since the occurrence of serious infections does not appear to be increased in RA patients treated with abatacept, this may be a preferred biologic option in patients with RA deemed to have increased risk for bacterial infection.

Rituximab

Depletion of CD20+ lymphocytes impacts primarily B cell-mediated acquired immunity and has little if any impact on the function of phagocytic cells. However, infection risk among RA patients treated with rituximab is nonetheless comparable to that observed among patients treated with TNF inhibitors [17, 19]. This may be due to the not insignificant numbers of patients who develop hypogammaglobulinemia with recurrent dosing of rituximab , with occurrence of serious infection events noted to be higher in such patients [20]. Management of intercurrent infections in patients treated with rituximab or other B cell-depleting reagents (such as obinutuzumab, ofatumumab) is therefore best directed toward ensuring antecedent B cell depletion therapy has not rendered the recipient hypogammaglobulinemic. Should severe infection occur with IgG levels less than 500 mg/dL, consideration should be given to supportive immunoglobulin replacement therapy (usually 0.4 g/kg every 4 weeks as needed). Whether to initiate prophylactic immunoglobulin replacement therapy at lower levels of serum IgG in the absence of infection is subject to debate. Hypogammaglobulinemia in the setting of B cell depletion therapy may be transient, and provided the patient can produce adequate neutralizing antibodies, IgG replacement therapy in such patients may not be required. Assessment of responses to pneumococcal vaccination may be informative in this setting. With this caveat of needed vigilance for hypogammaglobulinemia, given the absence of its effects on phagocytic cell functions, rituximab may be another preferred option for managing patients with RA who either have comorbidities placing them at increased risk for infections or who have experienced recurring episodes of bacterial infections on anti-TNF biologics.

Seronegative Spondyloarthropathies

Patients with seronegative spondyloarthropathies (SNSA) are at some increased risk for infection due to chronic arthropathy as well as enteric complications due to underlying inflammatory bowel disease (IBD) or subclinical inflammation of the enteric mucosa that may occur in non-IBD-associated SNSA (see Chap. 16). A noted increased occurrence of mannose-binding lectin (MBL) deficiency in patients with SNSA may also confer increased risk for infection [21, 22].

Methotrexate, sulfasalazine, and TNFα inhibitors are commonly employed in the management of SNSA, and the same considerations with regard to the use of these therapies in patients with RA are applicable and relevant to patients with SNSA with intercurrent infection. As discussed below, use of alternative biologics targeting the IL-23/IL-17 pathway that are primarily used in the management of psoriasis and SNSA may also need to be curtailed in the setting of intercurrent infection. Apremilast, a phosphodiesterase-4 inhibitor that is used primarily for the management of psoriasis and psoriatic arthropathy, does not have any direct effects on phagocytic cell function and has not been shown in clinical trials to confer increased infection risk [23]. As such, it is usually not necessary to curtail the use of apremilast during episodes of infection. The majority of joint manifestations in SNSA can otherwise be adequately managed with NSAID therapy during episodes of intercurrent infection when anti-TNF biologics or biologics targeting the IL23/IL17 axis need to be appropriately withheld.

Ustekinumab and IL-23 Inhibitors

Ustekinumab is a monoclonal reagent targeting the shared p40 subunit of the IL-12 and IL-23 receptors. Both IL-12 and IL-23 impact primarily T cell lineage development, with minimal if any direct effects on phagocytic cell functions. In clinical trials using ustekinumab in psoriasis as well as ankylosing spondylitis and inflammatory bowel disease, there have been no increased occurrences of serious infections in the ustekinumab treatment arms relative to the placebo treatment arms [24]. While there is no evidence to support holding ustekinumab or IL-23-specific therapies during intercurrent bacterial infection, given the identified role of IL-12 and IL-23 in mediating host defense against mycobacterial, fungal, and Salmonella infections, it is prudent to withhold ustekinumab and agents targeting IL-23 (tildrakizumab and guselkumab) in the setting of infection with these pathogens.

Inhibitors of IL-17 and IL-17R

IL-17 is derived from both innate and lymphoid cells, promoting the induction and release of IL-6, TNF, CCL2, CCL3, and matrix metalloproteinase (MMPs) from macrophages as well as the proliferation, maturation, and chemotaxis of neutrophils. In trials with secukinumab and ixekizumab (inhibitors of IL-17A) as well as trials with brodalumab (an inhibitor of the IL-17R), infection rates were increased over those observed in patients randomized to placebo but comparable to what has been observed in similar populations of patients enrolled in trials with TNF inhibitors [25]. Candida infections occurred more frequently in studies with the IL-17 inhibitor brodalumab [26]. It is prudent to withhold therapies targeting IL-17/IL-17R in the setting of active infection with these classes of microbial pathogens. For patients with SNSA who have experienced recurrent serious infections, consideration should be given to use of alternative therapies associated with less infection risk such as apremilast or ustekinumab. Although the therapeutic benefits of ustekinumab in SNSA may be attributable in large part to decreases in the number and survival of Th17 lymphocytes which comprise a significant source of IL-17, there are other (innate) cellular sources of IL-17 and therapies that specifically target IL-17 or its receptor may therefore confer greater infection risk than therapies targeting the Th17 lineage.

Systemic Lupus Erythematosus

For a variety of reasons, patients with systemic lupus erythematosus (SLE) may be at increased risk for infection (see Chap. 21). Defects in innate immunity related to opsonization functions known to also predispose to SLE include deficiencies in early components of the classic complement pathway (C1q, C2, and C4) and mannose-binding lectin [27, 28]. Lymphopenia is a common disease manifestation and a demonstrated risk factor for infectious complications in lupus [29]. Autoreactive T cell clones and/or autoantibodies may potentially target molecules required for appropriate production of granulocytes [30] or the ability of B cells to appropriately mature, proliferate, and secrete high-affinity antibodies capable of neutralizing microbial pathogens [31]. Autoimmunity with SLE features may be the presenting feature of patients with common variable immune deficiency or immunoglobulin IgG subclass deficiency [32]. Although therapies required to suppress autoreactive inflammatory disease are becoming increasingly selective and targeted (one example being belimumab), many of the current therapies required to effectively manage moderate to severe SLE activity result in some degree of nonselective immune suppression impacting innate and/or acquired immune functions.

Due primarily to their direct effects on the function of phagocytic cells as well as the production and survival of T lymphocytes, chronic corticosteroid therapy constitutes one of the major risk factors for infection-related morbidity and mortality in SLE patients. For patients who require ongoing treatment with corticosteroids, the dosing of steroids during intercurrent bacterial infection should be the lowest deemed sufficient to avoid SLE-related acute organ damage. In the setting of overwhelming confirmed microbial sepsis deemed life-threatening, it is usually prudent to decrease the dose of steroids to that required to avoid adrenal crisis, even if this entails a risk of SLE-related organ damage. The exception may be in the setting of active lupus-related CNS or pulmonary disease (notably diffuse alveolar hemorrhage) where corticosteroid dosing at high levels may be necessary to avoid imminent demise or brain injury. High-dose intravenous immunoglobulin (IVIG) (2.0 g/kg/day) is often effective in ameliorating acute lupus-related CNS vascular injury [33, 34] or alveolar hemorrhage [35] and should be considered as an alternative to high-dose steroid therapy when these entities require treatment in the setting of serious bacterial infection.

Dosing with cyclophosphamide or azathioprine, both of which may impact the numbers and production of phagocytic cells, is best withheld in the setting of bacterial infection. Moreover, should lupus patients develop significant granulocytopenia (<500/mcl) during treatment with either of these agents, prophylactic use of levofloxacin (500 mg/day) is recommended to decrease the risk of gram-negative sepsis until the absolute neutrophil count recovers to >500/mcl [36]. Treatment with recombinant granulocyte colony-stimulating factor (rCSF) can be considered if serious intercurrent bacterial infection occurs in this setting, but use of rCSF is otherwise not recommended due to increased risk of lupus flare associated with its use [37]. Since mycophenolate and mycophenolic acid target primarily the proliferation of lymphoid cells with minimal, if any, impact on the proliferation of phagocytic cells, it may not be necessary to withhold treatment with these agents during episodes of bacterial infection. Antimalarials (chloroquine, hydroxychloroquine, quinacrine), dapsone, and thalidomide have no significant impact on host responses to microbial pathogens and can be continued as needed to suppress lupus activity during episodes of infection. Since belimumab primarily impacts the maturation, proliferation, and survival of autoreactive B cells and has no known effects on phagocytic cell function, it is usually not necessary to withhold scheduled dosing with this biologic during periods of intercurrent infection. Provided patients who may be hypogammaglobulinemic (due to immunosuppression or underlying associated immunodeficiency) are receiving appropriate immunoglobulin replacement treatment in the setting of acute infectious complications, it may also not be necessary to withhold dosing with B cell-depleting agents such as rituximab or obinutuzumab if needed for managing acute disease complications such as immune thrombocytopenia or hemolytic anemia. However, temporizing measures using a course of high-dose IVIG (2 g/kg) may be a more prudent intervention for treating acute exacerbations of immune cytopenias in lupus patients with intercurrent serious microbial infection [38, 39].

Sjogren’s Syndrome

Patients with Sjogren’s syndrome may require immunosuppressive therapy for pulmonary complications such as acute interstitial lung disease or organizing pneumonia or neurologic complications such as transverse/longitudinal myelitis. Although corticosteroids and cytotoxic agents are often employed in the initial acute management of these complications, early initiation of steroid-sparing therapy with agents such as mycophenolate with minimal impact on phagocytic cell function may help mitigate infection risk. For patients with intercurrent infection who still have acute myelitis or other central nervous system disease, temporizing measures with use of high-dose IVIG may permit prompt lowering of the employed use of corticosteroids and holding of cytotoxic therapy without increasing the risk of clinical relapse [40]. For patients who develop infection in the setting of active interstitial lung disease or organizing pneumonia, lowering the dose of corticosteroids and use of IVIG with rituximab or mycophenolate may be an effective therapeutic alternative with minimal impact on host defenses required to clear intercurrent infection [41, 42, 43].

Systemic Sclerosis

Immunosuppressive therapy is being utilized more frequently in the management of patients with systemic sclerosis who have evidence of alveolitis or who have early active skin disease with dermal edema. Cyclophosphamide is used most commonly for patients with active interstitial lung disease and evidence of active alveolitis on high-resolution CT scan, with concomitant improvements also noted in selected patients with active skin disease. Notably, improvements have also been noted in both lung and skin manifestations among patients treated with mycophenolate [44]. Although not yet assessed in randomized trials, a number of small case series have reported improvements in both lung and skin manifestations following treatment with high-dose (2 g/kg) IVIG [45]. As such, for patients with active lung and skin disease who have ongoing infection complications that would best preclude use of cyclophosphamide, consideration can be given to using IVIG as a suitable alternative for managing acute lung inflammation and/or transitioning to mycophenolate for long-term management of these disease complications.

Polymyositis and Dermatomyositis

The standard management of inflammatory myopathies entails initial use of corticosteroids, most often in divided doses, with early initiation of steroid-sparing immunosuppressive therapy such as mycophenolate, azathioprine, methotrexate, or calcineurin inhibitors. Given the negligible effects of mycophenolate or calcineurin inhibitors on phagocytic cell proliferation and function, it may not be necessary to withhold these medications during treatment for routine bacterial infections. However, withholding mycophenolate and other immune suppressants is advisable in the setting of infection with opportunistic infections, whereby host T cell responses are critical in effecting clearance of the infecting pathogen. IVIG has demonstrated efficacy in both the acute and chronic management of polymyositis as well as dermatomyositis (including associated acute lung inflammation) and would be a preferred option for managing critical weakness and/or pneumonitis in patients with these disorders who have infection complications requiring attenuation of corticosteroid and other immunosuppressive therapy [46].

Vasculitis

Given the intensity of immune suppression often required to induce remission in patients with systemic vasculitis , infectious complications are not uncommon occurrences in patients with these disorders. Moreover, compromise of vascular integrity in patients with disease-involving vessels which supply the dermis and gastrointestinal tract may engender septic complications. Disease management may be further complicated by the propensity of intercurrent infection to trigger flares of disease. These considerations require careful vigilance for infection as well as careful attention to organ-specific disease activity when managing patients with systemic vasculitis.

ANCA-Associated Vasculitis

Infectious complications in patients with granulomatosis and polyangiitis (GPA) or microscopic polyangiitis (MPA) are of particular concern not only from the standpoint of sepsis-associated morbidity but also the possibility of disease flare triggered by neutrophil degranulation of target antigen (proteinase-3 and myeloperoxidase). Flares of ANCA-associated vasculitis and pauci-immune glomerulonephritis occurring in the context of bacteremia are well documented [47, 48, 49]. Vigilance for development of bacterial infection as well as antimicrobial prophylaxis is therefore a critical component of disease management strategies in patients with ANCA-associated vasculitis . Daily dosing with trimethoprim-sulfamethoxazole (160–800 mg) has been shown to decrease flares of GPA and is recommended as an adjunct treatment to immune suppression in patients with GPA as well as MPA [50]. Use of trimethoprim-sulfa would be of even greater importance to prevent infection with Pneumocystis jirovecii pneumonia in patients who may develop CD4+ T cell counts <300/mm3 as a consequence of sustained treatment with immune suppression regimens impacting T cells. Leucopenia in association with immunosuppressive therapy is a significant risk factor for sepsis and poor outcomes in ANCA-associated glomerulonephritis [51]. Accordingly, for patients receiving cyclophosphamide as part of their induction treatment or patients managed with azathioprine, prophylactic use of levofloxacin is recommended during periods of severe neutropenia that may occur as a complication of treatment with these immune suppressants [52]. Use of recombinant granulocyte colony-stimulating factor can be considered if intercurrent serious infection occurs but is otherwise best avoided due to potential increased risk of vasculitis flares that may be associated with its use [53].

Since B cell depletion treatments with rituximab, use of cyclophosphamide, or use of azathioprine in the management of ANCA vasculitis may engender hypogammaglobulinemia, it is important to check immunoglobulin levels when patients with ANCA vasculitis develop septic complications. Administration of immunoglobulin replacement therapy (0.4 g/kg) should be considered for patients with bacterial infection and serum IgG levels less than 500 mg/dL. Continuation of immunoglobulin replacement at 3–4-week intervals is recommended until the infection has resolved; longer treatment duration for patients with sustained hypogammaglobulinemia may decrease the likelihood of recurring infection [54].

Giant Cell Arteritis

The primary treatment for giant cell arteritis (GCA) is chronic corticosteroid therapy, placing affected patients at risk for routine as well as opportunistic infection. Optimal disease management of GCA during episodes of infection depends upon when in the course of disease septic complications occur. Should bacterial infection develop within the first month of diagnosis when patients with ophthalmic artery involvement may be at risk for visual loss, it may be necessary to continue prescribed steroid treatment in the setting of bacterial infection. Subsequent to this initial phase of treatment, temporary attenuation of corticosteroid dosing to doses required to avoid adrenal insufficiency can usually safely be undertaken until the infection has resolved.

Similar considerations as were discussed in RA management apply to the more recent use in GCA of anti-IL-6 therapy with tocilizumab, shown to increase the likelihood of GCA remission and lower the cumulative dose of corticosteroid required for management. Should infectious complications occur, treatment with anti-IL-6 therapy is best withheld until infection has resolved, with use of the lowest dose of corticosteroid deemed appropriate to manage the GCA at the time infection occurs. Due to the association of tocilizumab therapy with intestinal perforations and homeostatic role of IL-6 in maintenance of mucosal integrity, tocilizumab or other anti-IL6 therapies are best not resumed in patients with sepsis arising from the gastrointestinal tract [13, 14].

Polyarteritis Nodosa

Optimal management of polyarteritis nodosa (PAN ) varies depending upon whether the disease has been demonstrated to develop in the context of infection with viral pathogens such as hepatitis B (HBV), parvovirus B19, or cytomegalovirus. Induction strategies for HBV-associated PAN often entail combinations of a limited (2-week) course of corticosteroids and plasma exchange with antiviral therapy to induce remission [55], and CMV-associated polyarteritis is best managed with corticosteroids, ganciclovir, and either IVIG or anti-CMV immunoglobulin [56]. IVIG alone may be sufficient to effect resolution of parvovirus B19-associated PAN [57]. PAN syndromes in the absence of confirmed viral disease are most often managed with corticosteroids in combination with cyclophosphamide. Should septic complications occur during the prescribed treatment program, use of high-dose IVIG as a temporary alternative to cytotoxic therapy may serve to suppress vasculitis [58, 59]. However, for patients with neurologic or visceral complications of non-viral-associated PAN, the effects of IVIG are often just transient, and it is usually necessary to resume cytotoxic therapy to achieve disease remission.

Cryoglobulinemic Vasculitis

Similar to PAN, optimal management of cryoglobulin syndromes is based upon the disease process that has engendered the development of the cryoprecipitating immunoglobulins. Induction strategies entail combinations of plasma exchange with B cell depletion or alternative cytotoxic therapy for type I cryoglobulins associated with monoclonal gammopathies and type III cryoglobulin-associated autoimmune disease. Use of antiviral therapies with or without a brief course of corticosteroid therapy and plasma exchange constitute the most common strategies for management of severe or life-threatening type II cryoglobulins associated with hepatitis C infection. Rituximab may be added after viral clearance for persistent autoimmune manifestations (see Chap.  26). Should septic complications occur in the course of any of the above cryoglobulin syndromes, high-dose IVIG (2 g/kg) is an effective treatment strategy that can be employed to suppress vasculitis manifestations until intercurrent bacterial infection resolves. Bacterial infections occurring as a complication of plasma exchange may be due in part to associated hypogammaglobulinemia, and IVIG replacement therapy (0.4 g/kg) should be administered to such patients. However, administration of IVIG is not recommended in patients who have cryoglobulins associated with rheumatoid factor activity, as severe disease exacerbations have been reported when IVIG is administered in this setting [60, 61].

Management of Autoimmune Disorders in the Setting of Immune Deficiency

Immune deficiency may occur as a consequence of prescribed immunosuppressive therapy, genetic defects impacting development of mature immune responses, autoimmune responses targeting cells and/or molecules involved in the immune response, or viruses targeting immune effector cells. Since underlying immune deficiency may be an important consideration in the overall management strategy of autoimmune disease, assessment of underlying immune competence should be included in the initial if not ongoing assessment of individuals presenting with autoimmune manifestations.

Immune Deficiency Occurring as a Consequence of Autoimmune Disease Treatment

Although targeted therapies are becoming increasingly available as effective interventions for autoimmune disease, infectious complications due to treatment-related acquired immune deficiency remain a significant cause of disease morbidity and mortality. Accumulated experience with the use of chemotherapeutic agents impacting populations of immune cells has helped define thresholds below which infection complications are likely to occur. When using immune suppressants for treatment of autoimmune disease, periodic surveillance for acquired immune defects known to be associated with their use and employing prophylactic interventions when significant deficiency is recognized may serve to mitigate the risk of infection-related morbidity. Management of autoimmune disease going forward following recognition of treatment-related immune deficiency should include consideration of:
  1. 1.

    Attenuating the dose of prescribed immunosuppressive therapy as disease activity permits

     
  2. 2.

    Use of prophylactic interventions (Table 33.1)

     
  3. 3.

    Alternative therapeutic approaches that are least likely to compromise phagocytic cell functions as have been discussed for patients with autoimmune disease and intercurrent infection

     
Table 33.1

Risk mitigation in the setting of immunosuppressive treatment

Immune defect

Therapeutic agent(s)

Threshold

Intervention options

Neutropenia

Cyclophosphamide

Azathioprine

6-mercaptopurine

Methotrexate

<500/mm3

Levofloxacin 500 mg/day

T-lymphopenia

Corticosteroids

Cyclophosphamide

Azathioprine

6-mercaptopurine

Mycophenolic acid

<500/mm3

Trimethoprim-sulfa 160/800 mg q.o.d.

Dapsone 100 mg daily

Hypogammaglobulinemia

Corticosteroids (prolonged use)

Cyclophosphamide

Azathioprine

6-mercaptopurine

Mycophenolic acid

Anti-CD20 (rituximab)

<500 mg/dL (<700 mg/dL with infection)

IVIG 0.4 g/kg every 3–4 weeks

Immune Deficiency Occurring as a Consequence of Autoimmunity

Immune deficiency developing as a consequence of autoimmunity poses a significant therapeutic challenge, as the cell line(s) affected may be further impacted by therapies normally required to manage the underlying autoimmune process. Lymphopenia, neutropenia, and pancytopenia not uncommonly occur in the context of SLE. Autoimmune neutropenia and aplastic anemia occurring in the setting of lupus have been effectively managed with therapies primarily targeting autoreactive T lymphocytes, including cyclosporine, tacrolimus, or anti-thymocyte globulin. Severe peripheral lymphopenia is a hallmark of lupus activity, but the underlying mechanisms giving rise to lymphopenia are not well understood and the extent to which the noted lymphopenia increases infection risk in SLE has not been well defined.

In the presence or absence of lymphopenia, hypogammaglobulinemia may occur in patients with established SLE [62]. For patients in whom low immunoglobulin levels are noted to antedate SLE manifestations, the underlying immunopathology may comprise part of the spectrum of common variable immune deficiency (discussed below). Alternatively, hypogammaglobulinemia may develop in the absence of significant immunosuppressive therapy well into the course of SLE [63, 64]. In such cases, it is hypothesized that autoimmune responses develop that target B cells directly or growth factors or cytokines requisite for B cell maturation and survival. Notably, it has been observed that in patients who develop spontaneous B cell depletion, preceding lupus manifestations may remit [65]. For patients who otherwise continue to have active disease manifestations requiring immune suppression, institution of immunoglobulin replacement therapy may permit proceeding as needed with usual SLE standard of care interventions [62].

Immune Deficiency Occurring as the Primary Disorder Underlying Autoimmunity

Manifestations of autoimmunity are not uncommonly an initial presenting clinical feature in patients with primary immune deficiencies (PID). With the advent of whole genome sequencing, increasing numbers of identified mutations underlying PID have been identified, many of which may be associated with autoimmunity (Table 33.2). The temporal relationships underlying the development of infection-related versus autoimmune complications arising from the underlying immune dysfunction are highly variable, and the mechanisms underlying the development of autoimmunity in these disorders remain incompletely understood. However, there is a developing collection of experience with management of autoimmunity associated with the more common and better characterized primary immune deficiencies (see Chap.  4).
Table 33.2

Primary immune deficiencies associated with autoimmunity

Disorder

Mutations

Immune defects

Autoimmune features

CVID

TACI, others

Hypogammaglobulinemia

AIHA, ITP, SLE, (multiple)

sIgAD

 

Low serum IgA

JIA, RA, SLE

Celiac disease

Hashimoto’s thyroiditis

Pernicious anemia

Myasthenia gravis

Dermatomyositis

X-linked agammaglobulinemia

btk

Hypogammaglobulinemia

FcR, TLR signaling

(rare)

Hyper-IgM [1]

CD40, CD40 ligand

Low serum IgG

T cell co-stimulation

(rare)

Hyper-IgM [2], hyper-IgM [3]

AICDA, UNG

Low serum IgG

Autoimmune hepatitis

RA, IBD, uveitis

Diabetes mellitus

MBL deficiency

MBL2

Opsonization

SLE

C1q, C2, C4

C1q, C2, C4A/C4B

Opsonization

SLE

Adenosine deaminase deficiency

ADA

Th, T reg, variable low IgG

AIHA, ITP

PNP deficiency

PNP

Th, T reg, variable low IgG

AIHA, ITP

Wiskot-Aldrich syndrome

WAS

Th, T reg

AIHA, ITP, IBD, vasculitis, glomerulonephritis

DiGeorge syndrome

22q11 deletions

Th, T reg

AIHA, ITP, IBD, thyroiditis

LRBA deficiency

LRBA

T reg, low serum IgG

AIHA, ITP, enteritis, arthritis, myasthenia gravis, encephalitis, cerebellitis

CHAI

CTLA4

Th, T reg, variable low IgG

AIHA, ITP, enteritis, pneumonitis

AICDA activation-induced cytodine deaminase, AIHA autoimmune hemolytic anemia, CHAI CTLA-4 haploinsufficiency with autoimmune infiltration, CVID common variable immune deficiency, IBD inflammatory bowel disease, ITP immune thrombocytopenia, JIA juvenile idiopathic arthritis, LRBA lipopolysaccharide (LPS)-responsive beige-like anchor, MBL mannose bonding lectin, PNP purine nucleoside phosphorylase, sIgAD selective IgA deficiency, TACI transmembrane activator calcium-modulator and cyclophilin ligand interactor, TLR toll-like receptor, UNG uracil nucleoside glycosalase

Common variable immune deficiency (CVID) is the disorder in which autoimmunity is most commonly linked to immune deficiency. The prevalent immunologic phenotype is hypogammaglobulinemia with low levels of IgG and inability to generate sufficient IgG antibodies in response to pneumococcal or other polysaccharide bacterial antigens. Levels of IgA and/or IgM in CVID may also be attenuated. The mechanisms underlying the immune deficiency are variable; those most well described are failures of immunoglobulin class switch due to mutations in the transmembrane activator, calcium-modulator, and cyclophilin ligand interactor (TACI) receptor, but these account for less than 20% of affected patients [66]. While most patients with CVID have a history of recurring bacterial infections dating to childhood, many patients noted to have clinical and immunologic features consistent with CVID do not develop recurring infections or hypoglobulinemia until the third, fourth, fifth, or even later decades of life [67], begging the question as to whether the immune deficiency in such patients develops as a consequence of autoreactive responses targeting the normal production of mature neutralizing antibodies.

Preventative strategies are employed to minimize infectious complications associated with CVID and to permit management of associated autoimmunity with less infection risk. Milder variants associated with recurring respiratory infections can be successfully managed with rotating antibiotic therapy targeting respiratory pathogens. For patients with more severe levels of hypogammaglobulinemia (less than 500 mg/dL) and/or those demonstrating failure to mount sufficient titers of neutralizing antibodies in response to administered vaccine antigens, intravenous (every 3–4 week) or weekly subcutaneous infusions of immunoglobulin replacement therapy are recommended. Although complete selective IgA deficiency is uncommon in CVID, assessment for this is advised to minimize risk of anaphylaxis with IVIG administration. For CVID patients with significant intercurrent infection complications or undergoing major surgery, an additional dose of IVIG (0.4 g/kg) is recommended.

Immune thrombocytopenia, autoimmune hemolytic anemia, neuromyelitis optica, anti-GAD65 dystonias, ANCA vasculitis, or other CVID-associated autoimmune complications associated with defined autoantibodies frequently respond favorably to rituximab in combination with scheduled IVIG replacement therapy [68, 69, 70, 71]. A similar therapeutic approach may be effective in managing the granulomatous interstitial lung disease that is not uncommonly associated with CVID [72, 73]. Lupus-related musculoskeletal and cutaneous syndromes that develop on a background of CVID can frequently be managed effectively with antimalarials, weekly methotrexate, and/or dapsone, without requiring significant corticosteroid use. As these drugs do not significantly impact B cell proliferation, the use of background immunoglobulin replacement therapy may not be required in patients who have these lupus-related features in association with milder variants of CVID. The use of immunosuppressive therapies that do impact B cell populations is otherwise best undertaken in CVID patients on a background of immunoglobulin replacement therapy.

Patients with CVID with or without known autoimmunity have been observed to have higher than normal levels of B lymphocyte stimulator (BLyS, BAFF), a known survival factor for autoreactive B cells [74]. Whether and to what extent elevated levels of BLyS/BAFF contribute to autoimmunity in CVID remain an active area of investigation. The noted elevations in BLyS/BAFF in patients with CVID suggest that presently available biologic reagents which neutralize the effects of BLyS/BAFF may be potentially useful in suppressing autoimmune complications in this population of patients.

Selective IgA Deficiency (sIgAD) is commonly associated with a variety of autoimmune disorders, and case-control cohort studies have demonstrated greater prevalence of autoantibodies in IgA deficient patients [75, 76]. The immunopathologic mechanisms underlying noted increases in autoimmunity in sIgAD individuals remain poorly understood, but associations with deficiencies in the population of Treg cells and class-switched memory B cells have been observed in sIgAD cohorts with autoimmunity [77]. Since the vast majority of patients with sIgAD in the absence of IgG or IgG subclass deficiency do not have increased prevalence of serious infections, management of autoimmune and rheumatic disease in sIgAD patients can proceed as would be custom for patients who are not IgA deficient.

X-linked agammaglobulinemia (XLA) , associated with mutations in Bruton’s tyrosine kinase (btk) resulting in absence of circulating CD19+/CD20+ B cells and hypogammaglobulinemia, is rarely associated with autoimmune disease. In addition to being critical to normal B cell maturation, btk also mediates monocyte Fc receptor as well as toll-like receptor (TLR)-associated signal transduction, and in a variety of murine models of autoimmune inflammation, btk inhibitors have a profound ameliorative effect on tissue inflammation as well as titers of autoantibodies [78, 79]. The paucity of autoimmune complications in patients with btk deficiency is therefore not surprising and selective btk inhibitors are now being evaluated in clinical trials of patients with lupus. However, should autoimmune complications occur in a patient with XLA, treatment with indicated immunosuppressive therapy can proceed on a background of immunoglobulin replacement therapy.

Hyper IgM syndromes occur most commonly in the setting of CD40 or CD40 ligand deficiency, whereby there are observed failures of Ig class switching, establishment of effective cell memory, and T cell-driven monocyte activation. Laboratory correlates include low levels of IgG and IgA but normal to elevated levels of serum IgM, normal levels of circulating B cells but only expressing IgM or IgD, and absence of circulating memory B cells [80]. Clinical features include frequent respiratory infections and opportunistic infections (histoplasmosis, cryptosporidium, pneumocystis). Given the pivotal role of CD40-CD40 ligand interactions in T cell co-stimulation, it is therefore not surprising that autoimmune complications are seen rarely in patients with deficiency in CD40-mediated signaling and that interruptions in CD40-CD40L signaling can ameliorate autoimmune manifestations in lupus-prone mice.

In a small minority of cases (<5%), hyper IgM syndrome occurs due to deficiencies in either activation-induced cytidine deaminase (AICDA) or uracil nucleoside glycosylase (UNG). Both enzymes are required for B cell class switching, and deficiency of either results in low serum levels of IgG and IgA, with normal to high serum levels of IgM and normal levels of circulating B cells expressing IgM [81, 82]. However, unlike CD40/CD40L deficiency, T cell number and functions are essentially intact, and a variety of autoimmune complications have been reported in individuals deficient in AICDA or UNG including autoimmune hepatitis, RA, IBD, uveitis, and diabetes mellitus. Provided they are administered on a background of scheduled immunoglobulin replacement therapy, standard treatments can be employed to manage AICDA- and UNG-associated autoimmune complications.

Complement (C1q, C2, C4) and mannose-binding lectin (MBL) deficiencies are associated with increased risk of pyogenic infection with encapsulated organisms. Early complement components as well as MBL also opsonize and facilitate the removal by macrophages of nucleosome products of cellular apoptosis, rather than by plasmacytoid dendritic cells in a manner that renders epitopes in the nucleosomes becoming potentially immunogenic [83]. Deficiencies in C1q, C2, C4, and MBL have all been associated with increased risk of systemic or cutaneous lupus, presumably due to associated impairment in the noninflammatory, non-immunogenic disposal of apoptotic nucleosomes [28, 84]. Management of lupus-related autoimmune disease in patients with early complement or MBL deficiency can proceed with standard lupus therapies. However, it is prudent to monitor for treatment-associated lymphopenia, neutropenia, and hypogammaglobulinemia in affected patients, entertaining a lower threshold for instituting immunoglobulin replacement therapy or prophylactic antibiotic use in patients further immunocompromised (Table 33.1).

Adenosine deaminase deficiency ( ADA ) , Wiskott-Aldrich syndrome ( WAS ) , and DiGeorge (22q11 deletion) syndrome s are combined immune deficiencies associated with defects primarily in T cell function, with variable defects in humoral immunity arising secondarily. Autoimmunity occurs in these syndromes likely due in large part to impairments in the function and/or numbers of T regulatory lymphocytes.

The elevated levels of adenosine and deoxyadenosine associated with ADA are toxic primarily to T lymphocytes, engender feedback inhibition of ribonucleotide reductase with decreased de novo purine synthesis, and inhibit phagocytic cell migration. The primary observed immunologic abnormalities in ADA are very low levels of circulating T cells with variable degrees of hypogammaglobulinemia; immune cytopenias are the most commonly observed autoimmune complications. The noted autoimmunity observed in ADA likely occurs as a consequence of imbalances in the proportions of affected regulatory versus helper/cytotoxic T cells [85].

WAS develops primarily due to loss of function mutations of the WASp protein involved in the cytoskeletal functions of hematopoietic cells. The immunodeficiency develops due to loss of formation of lipid rafts required for the formation of the immunologic synapse between T lymphocytes and antigen-presenting cells. This WASp-associated cytoskeletal defect also likely accounts for the failure of T regs to form synapses with effector T cells, with attendant failure to suppress effector functions of autoreactive T lymphocytes [86]. As a consequence, autoimmune manifestations including immune cytopenias, vasculitis, IBD, and/or nephritis occur commonly in patients with WAS.

Individuals with DiGeorge syndrome due to deletions of 22q11 have impaired thymic development with low numbers of circulating T lymphocytes. Reported autoimmune complications include immune cytopenias, endocrinopathies, and inflammatory enteropathies [87]. Autoimmunity in DiGeorge syndrome likely occurs as consequence of impaired development of a sufficiently diverse T regulatory cell repertoire [88].

Although management of autoimmune complications in patients with primary immune deficiencies is challenging, the majority of affected patients can be effectively managed with standard therapies employed in the treatment of nonimmune deficient individuals. It is nonetheless important to recognize the presence of primary immune deficiency in patients presenting with autoimmunity so as to appropriately choose and minimize the risk of infection that may be heightened as a consequence of employed immunosuppressive therapy. The development of an autoimmune disorder at an unusually early age for that condition, the presence of autoimmunity affecting multiple organ systems, or atypical immune syndromes that cannot be attributed to specific rheumatologic diagnosis should prompt investigation for possible primary immune deficiency. Assessment of immunoglobulin levels, responses to pneumococcal vaccination, and flow cytometry studies to quantify numbers of circulating B cells and T cell subset populations may serve as useful initial screening assessments for many of the immune deficiencies associated with autoimmunity.

References

  1. 1.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.CrossRefGoogle Scholar
  2. 2.
    Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res. 2014;66(7):990.CrossRefGoogle Scholar
  3. 3.
    Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, et al. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy. J Rheumatol. 2015;42:372–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Goodman SM. Rheumatoid arthritis: perioperative management of biologics and DMARDs. Semin Arthritis Rheum. 2015;44:627–32.CrossRefPubMedGoogle Scholar
  6. 6.
    Chan ES, Cronstein BN. Methotrexate – how does it really work? Nat Rev Rheumatol. 2010;6:175–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002;103:13–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47:268–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Dorhoi A, Kaufmann SH. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol. 2014;26:203–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study. Ann Rheum Dis. 2014;73:1942–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Wasson NJ, Varley CD, Schwab P, Fu R, Winthrop KL. Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study. BMC Infect Dis. 2013;13:533.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113–8.PubMedGoogle Scholar
  13. 13.
    Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76:504–10.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Strand V, Ahadieh S, French J, Geier J, Krishnaswami S, Menon S, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, et al. Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res. 2016;68:1078–88.CrossRefGoogle Scholar
  17. 17.
    Yun H, Xie F, Delzell E, Levitan EB, Chen L, Lewis JD, et al. Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol. 2016;68:56–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86–94.CrossRefPubMedGoogle Scholar
  19. 19.
    Silva-Fernandez L, De Cock D, Lunt M, Low AS, Watson KD, Group B-RC, et al. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from the British Society for Rheumatology biologics register for rheumatoid arthritis. Rheumatology. 2017.  https://doi.org/10.1093/rheumatology/kex304.
  20. 20.
    van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72:1496–502.CrossRefPubMedGoogle Scholar
  21. 21.
    Nisihara R, Skare T, Maestri V, Alegretti JS, Campos APB, Messias-Reason I. Mannose-binding lectin (MBL) deficiency and tuberculosis infection in patients with ankylosing spondylitis. Clin Rheumatol. 2017;37(2):555–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Skare TL, Nisihara R, Cieslinski JZ, Zeni JO, Rasera HN, Messias-Reason I, et al. Mannose-binding lectin deficiency in Brazilian patients with spondyloarthritis. Immunol Investig. 2017;46:183–9.CrossRefGoogle Scholar
  23. 23.
    Crowley J, Thaci D, Joly P, Peris K, Papp KA, Goncalves J, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017;77:310–7e1.CrossRefPubMedGoogle Scholar
  24. 24.
    Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis – results of two phase 3 trials. N Engl J Med. 2014;371:326–38.CrossRefPubMedGoogle Scholar
  26. 26.
    Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177:47–62.CrossRefPubMedGoogle Scholar
  27. 27.
    Yang Y, Chung EK, Zhou B, Lhotta K, Hebert LA, Birmingham DJ, et al. The intricate role of complement component C4 in human systemic lupus erythematosus. Curr Dir Autoimmun. 2004;7:98–132.CrossRefPubMedGoogle Scholar
  28. 28.
    Monticielo OA, Mucenic T, Xavier RM, Brenol JC, Chies JA. The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol. 2008;27:413–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Merayo-Chalico J, Gomez-Martin D, Pineirua-Menendez A, Santana-De Anda K, Alcocer-Varela J. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study. QJM. 2013;106:451–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Hartman KR. Anti-neutrophil antibodies of the immunoglobulin M class in autoimmune neutropenia. Am J Med Sci. 1994;308:102–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Browne SK. Anticytokine autoantibody-associated immunodeficiency. Annu Rev Immunol. 2014;32:635–57.CrossRefPubMedGoogle Scholar
  32. 32.
    Perazzio SF, Granados A, Salomao R, Silva NP, Carneiro-Sampaio M, Andrade LE. High frequency of immunodeficiency-like states in systemic lupus erythematosus: a cross-sectional study in 300 consecutive patients. Rheumatology. 2016;55:1647–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Engel G, van Vollenhoven RF. Treatment of severe CNS lupus with intravenous immunoglobulin. J Clin Rheumatol. 1999;5:228–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Rodrigues M, Galego O, Costa C, Jesus D, Carvalho P, Santiago M, et al. Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre. Lupus. 2017;26:1440–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Deane KD, West SG. Antiphospholipid antibodies as a cause of pulmonary capillaritis and diffuse alveolar hemorrhage: a case series and literature review. Semin Arthritis Rheum. 2005;35:154–65.CrossRefPubMedGoogle Scholar
  36. 36.
    Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C, et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis. 2008;27:53–63.CrossRefPubMedGoogle Scholar
  37. 37.
    Euler HH, Harten P, Zeuner RA, Schwab UM. Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections. J Rheumatol. 1997;24:2153–7.PubMedGoogle Scholar
  38. 38.
    Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol. 2002;29:75–83.PubMedGoogle Scholar
  39. 39.
    Gomard-Mennesson E, Ruivard M, Koenig M, Woods A, Magy N, Ninet J, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006;15:223–31.CrossRefPubMedGoogle Scholar
  40. 40.
    Rogers SJ, Williams CS, Roman GC. Myelopathy in Sjogren’s syndrome: role of nonsteroidal immunosuppressants. Drugs. 2004;64:123–32.CrossRefPubMedGoogle Scholar
  41. 41.
    Gueta I, Shoenfeld Y, Orbach H. Intravenous immune globulins (IVIg) treatment for organizing pneumonia in a selective IgG immune deficiency state. Immunol Res. 2014;60:165–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Kashif M, Arya D, Niazi M, Khaja M. A rare case of necrotizing myopathy and fibrinous and organizing pneumonia with anti-EJ antisynthetase syndrome and SSA antibodies. Am J Case Rep. 2017;18:448–53.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Shitenberg D, Fruchter O, Fridel L, Kramer MR. Successful rituximab therapy in steroid-resistant, cryptogenic organizing pneumonia: a case series. Respiration. 2015;90:155–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69:1451–60.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Cantarini L, Rigante D, Vitale A, Napodano S, Sakkas LI, Bogdanos DP, et al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res. 2015;61:326–37.CrossRefPubMedGoogle Scholar
  46. 46.
    Wang DX, Shu XM, Tian XL, Chen F, Zu N, Ma L, et al. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Clin Rheumatol. 2012;31:801–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Hellmich B, Ehren M, Lindstaedt M, Meyer M, Pfohl M, Schatz H. Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. Clin Rheumatol. 2001;20:441–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Kasmani R, Okoli K, Naraharisetty K, Gunning W, Shapiro JI, Ratnam S. Microscopic polyangiitis triggered by recurrent methicillin-resistant Staphylococcus aureus bacteremia. Int Urol Nephrol. 2010;42:821–4.CrossRefPubMedGoogle Scholar
  49. 49.
    Bell EK, Chugh SS, Cook WJ. A case of infection-associated antiproteinase-3-negative cytoplasmic antineutrophil cytoplasmic antibody pauci-immune focal necrotizing glomerulonephritis. Nephrol Dial Transplant. 2010;25:3119–23.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996;335:16–20.CrossRefPubMedGoogle Scholar
  51. 51.
    Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41:776–84.CrossRefPubMedGoogle Scholar
  52. 52.
    Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–87.CrossRefPubMedGoogle Scholar
  53. 53.
    Freeley SJ, Coughlan AM, Popat RJ, Dunn-Walters DK, Robson MG. Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis. Ann Rheum Dis. 2013;72:1053–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun. 2015;57:24–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004;51:482–7.CrossRefPubMedGoogle Scholar
  56. 56.
    Meyer MF, Hellmich B, Kotterba S, Schatz H. Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? Rheumatol Int. 2000;20:35–8.CrossRefPubMedGoogle Scholar
  57. 57.
    Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med. 2001;344:1481–2.CrossRefPubMedGoogle Scholar
  58. 58.
    Marie I, Miranda S, Girszyn N, Soubrane JC, Vandhuick T, Levesque H. Intravenous immunoglobulins as treatment of severe cutaneous polyarteritis nodosa. Intern Med J. 2012;42:459–62.CrossRefPubMedGoogle Scholar
  59. 59.
    Balbir-Gurman A, Nahir AM, Braun-Moscovici Y. Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature. Clin Exp Rheumatol. 2007;25:S28–30.PubMedGoogle Scholar
  60. 60.
    Barton JC, Herrera GA, Galla JH, Bertoli LF, Work J, Koopman WJ. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med. 1987;82:624–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Yebra M, Barrios Y, Rincon J, Sanjuan I, Diaz-Espada F. Severe cutaneous vasculitis following intravenous infusion of gammaglobulin in a patient with type II mixed cryoglobulinemia. Clin Exp Rheumatol. 2002;20:225–7.PubMedGoogle Scholar
  62. 62.
    Karim MY. Immunodeficiency in the lupus clinic. Lupus. 2006;15:127–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Stein A, Winkelstein A, Agarwal A. Concurrent systemic lupus erythematosus and common variable hypogammaglobulinemia. Arthritis Rheum. 1985;28:462–5.CrossRefPubMedGoogle Scholar
  64. 64.
    Baum CG, Chiorazzi N, Frankel S, Shepherd GM. Conversion of systemic lupus erythematosus to common variable hypogammaglobulinemia. Am J Med. 1989;87:449–56.CrossRefPubMedGoogle Scholar
  65. 65.
    Tarrant TK, Frazer DH, Aya-Ay JP, Patel DD. B cell loss leading to remission in severe systemic lupus erythematosus. J Rheumatol. 2003;30:412–4.PubMedGoogle Scholar
  66. 66.
    Sathkumara HD, De Silva NR, Handunnetti S, De Silva AD. Genetics of common variable immunodeficiency: role of transmembrane activator and calcium modulator and cyclophilin ligand interactor. Int J Immunogenet. 2015;42:239–53.CrossRefPubMedGoogle Scholar
  67. 67.
    Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34–48.CrossRefPubMedGoogle Scholar
  68. 68.
    Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011;155:498–508.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Hill F, Yonkof J, Chaitanya Arudra SK, Thomas J, Altorok N. Successful treatment of ANCA-associated vasculitis in the setting of common variable immunodeficiency using rituximab. Am J Ther. 2016;23:e1239–45.CrossRefPubMedGoogle Scholar
  70. 70.
    Zephir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, et al. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262:2329–35.CrossRefPubMedGoogle Scholar
  71. 71.
    Rizzi M, Knoth R, Hampe CS, Lorenz P, Gougeon ML, Lemercier B, et al. Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome. PLoS One. 2010;5:e10838.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Pathria M, Urbine D, Zumberg MS, Guarderas J. Management of granulomatous lymphocytic interstitial lung disease in a patient with common variable immune deficiency. BMJ Case Rep.2016;2016. https://doi.org/10.1136/bcr-2016-215624.
  73. 73.
    Jolles S, Carne E, Brouns M, El-Shanawany T, Williams P, Marshall C, et al. FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Exp Immunol. 2017;187:138–45.CrossRefPubMedGoogle Scholar
  74. 74.
    Knight AK, Radigan L, Marron T, Langs A, Zhang L, Cunningham-Rundles C. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency. Clin Immunol. 2007;124:182–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Barka N, Shen GQ, Shoenfeld Y, Alosachie IJ, Gershwin ME, Reyes H, et al. Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A deficiency. Clin Diagn Lab Immunol. 1995;2:469–72.PubMedPubMedCentralGoogle Scholar
  76. 76.
    Edwards E, Razvi S, Cunningham-Rundles C. IgA deficiency: clinical correlates and responses to pneumococcal vaccine. Clin Immunol. 2004;111:93–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Abolhassani H, Gharib B, Shahinpour S, Masoom SN, Havaei A, Mirminachi B, et al. Autoimmunity in patients with selective IgA deficiency. J Investig Allergol Clin Immunol. 2015;25:112–9.PubMedGoogle Scholar
  78. 78.
    Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, et al. Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fc gamma Receptor (FcgammaR) function. J Biol Chem. 2016;291:3043–52.CrossRefPubMedGoogle Scholar
  79. 79.
    Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, et al. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis. J Immunol. 2013;191:4540–50.CrossRefPubMedGoogle Scholar
  80. 80.
    Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82:373–84.CrossRefPubMedGoogle Scholar
  81. 81.
    Quartier P, Bustamante J, Sanal O, Plebani A, Debre M, Deville A, et al. Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to activation-induced Cytidine Deaminase deficiency. Clin Immunol. 2004;110:22–9.CrossRefPubMedGoogle Scholar
  82. 82.
    Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat Immunol. 2003;4:1023–8.CrossRefGoogle Scholar
  83. 83.
    Gullstrand B, Martensson U, Sturfelt G, Bengtsson AA, Truedsson L. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol. 2009;156:303–11.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Lood C, Gullstrand B, Truedsson L, Olin AI, Alm GV, Ronnblom L, et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 2009;60:3081–90.CrossRefPubMedGoogle Scholar
  85. 85.
    Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012;119:1428–39.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Humblet-Baron S, Sather B, Anover S, Becker-Herman S, Kasprowicz DJ, Khim S, et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117:407–18.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Tison BE, Nicholas SK, Abramson SL, Hanson IC, Paul ME, Seeborg FO, et al. Autoimmunity in a cohort of 130 pediatric patients with partial DiGeorge syndrome. J Allergy Clin Immunol. 2011;128:1115–7e1-3.CrossRefPubMedGoogle Scholar
  88. 88.
    Ferrando-Martinez S, Lorente R, Gurbindo D, De Jose MI, Leal M, Munoz-Fernandez MA, et al. Low thymic output, peripheral homeostasis deregulation, and hastened regulatory T cells differentiation in children with 22q11.2 deletion syndrome. J Pediatr. 2014;164:882–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.University of Alabama at Birmingham (UAB), Division of Clinical Immunology and RheumatologyBirminghamUSA

Personalised recommendations